1. Home
  2. PRG vs NVAX Comparison

PRG vs NVAX Comparison

Compare PRG & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$33.27

Market Cap

1.4B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.70

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
NVAX
Founded
2020
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
PRG
NVAX
Price
$33.27
$8.70
Analyst Decision
Buy
Hold
Analyst Count
7
9
Target Price
$37.67
$10.78
AVG Volume (30 Days)
434.0K
5.9M
Earning Date
02-18-2026
02-26-2026
Dividend Yield
1.56%
N/A
EPS Growth
10.59
N/A
EPS
3.96
2.07
Revenue
$2,507,179,000.00
$1,064,651,000.00
Revenue This Year
$1.24
$58.91
Revenue Next Year
$6.26
N/A
P/E Ratio
$8.43
$4.20
Revenue Growth
3.71
20.27
52 Week Low
$23.50
$5.01
52 Week High
$43.97
$10.65

Technical Indicators

Market Signals
Indicator
PRG
NVAX
Relative Strength Index (RSI) 51.81 52.89
Support Level $32.61 $8.25
Resistance Level $35.31 $9.28
Average True Range (ATR) 1.18 0.58
MACD -0.10 -0.09
Stochastic Oscillator 34.56 36.15

Price Performance

Historical Comparison
PRG
NVAX

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: